OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) and Provention Bio Inc. (NASDAQ:PRVB) compete with each other in the Biotechnology sector. We will analyze and compare their profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OncoMed Pharmaceuticals Inc.	54.88M	0.55	6.03M	0.13	7.15
Provention Bio Inc.	N/A	0.00	24.88M	-0.74	0.00

Table 1 highlights OncoMed Pharmaceuticals Inc. and Provention Bio Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides OncoMed Pharmaceuticals Inc. and Provention Bio Inc.’s return on equity, net margins and return on assets.

	Net Margins	Return on Equity	Return on Assets
OncoMed Pharmaceuticals Inc.	10.99%	25.8%	6.5%
Provention Bio Inc.	0.00%	0%	0%

Liquidity

OncoMed Pharmaceuticals Inc. has a Current Ratio of 3.4 and a Quick Ratio of 3.4. Competitively, Provention Bio Inc.’s Current Ratio is 53.7 and has 53.7 Quick Ratio. Provention Bio Inc.’s better ability to pay short and long-term obligations than OncoMed Pharmaceuticals Inc.

Analyst Ratings

OncoMed Pharmaceuticals Inc. and Provention Bio Inc. Recommendations and Ratings are available in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
OncoMed Pharmaceuticals Inc.	0	1	0	2.00
Provention Bio Inc.	0	0	0	0.00

OncoMed Pharmaceuticals Inc.’s upside potential currently stands at 92.73% and an $1.5 consensus target price.

Institutional & Insider Ownership

Institutional investors owned 64.9% of OncoMed Pharmaceuticals Inc. shares and 6.7% of Provention Bio Inc. shares. OncoMed Pharmaceuticals Inc.’s share owned by insiders are 0.7%. Insiders Competitively, owned 31% of Provention Bio Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
OncoMed Pharmaceuticals Inc.	-20.51%	-45.61%	-62.5%	-67.48%	-81.29%	-77.32%
Provention Bio Inc.	12.12%	-23.82%	-32.02%	0%	0%	-46.15%

For the past year Provention Bio Inc. has weaker performance than OncoMed Pharmaceuticals Inc.

Summary

OncoMed Pharmaceuticals Inc. beats on 9 of the 11 factors Provention Bio Inc.

OncoMed Pharmaceuticals, Inc. discovers and develops cancer stem cell (CSC) and immuno-oncology therapeutics. The companyÂ’s product candidates and preclinical programs include demcizumab (anti-DLL4, OMP-21M18), a humanized monoclonal antibody, in Phase II trial for pancreatic cancer, a randomized Phase II trial in non-small cell lung cancer, and a Phase Ib trial for solid tumor; tarextumab (anti-Notch2/3, OMP-59R5) that targets the Notch2 and Notch3 receptors, which is in Phase II clinical trial for small cell lung cancer; vantictumab (anti-Fzd, OMP-18R5) in two Phase Ib clinical trials for breast and pancreatic cancer; ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based on Frizzled8 receptor, which is in two Phase Ib clinical trials for ovarian and pancreatic cancer; and navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets DLL4 and vascular endothelial growth factor, which is in Phase Ia single-agent clinical trial for solid tumors, and two Phase Ib clinical trial for ovarian and metastatic colorectal cancer. It is also developing anti-RSPO3 (OMP-131R10), a monoclonal antibody, in Phase Ia/b clinical trial for solid tumor and metastatic colorectal cancer; brontictuzumab (anti-Notch1, OMP-52M51) targeting the Notch1 receptor, in Phase Ib clinical trial for colorectal cancer; anti-tigit (OMP-313M32), a T-cell immunoglobulin and ITIM domain protein, in Phase I clinical trial for tumor; and GITRL-Fc trimer (OMP-336B11), a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor and its ligand. The company has strategic alliances with GlaxoSmithKline LLC to develop and commercialize antibody therapeutics targeting the Notch signaling pathway; Bayer Pharma AG for biologic and small molecule therapeutics targeting the Wnt signaling pathway; and Celgene Corporation for anti-CSC product candidates. The company was founded in 2004 and is headquartered in Redwood City, California.

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, oral CSF-1R inhibitor, which is in Phase 2a clinical trial for the treatment of Crohn's disease; PRV-300, anti-TLR3 mAb, which is in Phase 1b clinical trial for the treatment of ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D. The company was incorporated in 2016 and is based in Oldwick, New Jersey.